<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> (ATLS) is a well-known complication of chemotherapy in patients with rapidly proliferative <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e> such as <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Rituximab anti-CD20 monoclonal antibody, an alternative to chemotherapy in the treatment of low-grade follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, also has been associated with ATLS </plain></SENT>
<SENT sid="2" pm="."><plain>Rituximab-induced ATLS has been reported in 2 patients with <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> and in 2 patients with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>I report another case of rituximab-induced ATLS in a patient with diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and review the cases in the literature </plain></SENT>
</text></document>